Screener
Allogene Therapeutics ALLO Operating Lease Liability - Undiscounted Excess Amount
Operating Lease Liability - Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's operating lease liability - undiscounted excess amount?
- Allogene Therapeutics (ALLO) reported operating lease liability - undiscounted excess amount of $21.64M in Q1 2026.
- How has Allogene Therapeutics's operating lease liability - undiscounted excess amount changed year-over-year?
- Allogene Therapeutics's operating lease liability - undiscounted excess amount decreased by 19.9% year-over-year, from $27.02M to $21.64M.
- What does operating lease liability - undiscounted excess amount mean?
- This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.
Ask your AI about Allogene Therapeutics's operating lease liability - undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude